



Amarin Corporation plc  
 Investor Relations Department  
 2 Pembroke House, Upper  
 Pembroke  
 Street 28-32  
 Dublin 2  
 Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AMRN**

Last Trade:	3.33
Trade Time:	4:00 PM ET Oct 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	2.75 - 4.47
Volume	N/A

Stock information is provided by eSignal,  
 stock charts provided by EDGAR Online.  
 Stock data is delayed approximately 20  
 minutes.

**Company Profile**

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Sep 25, 2017*  
[Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in Canada](#)
- Sep 20, 2017*  
[Amarin to Present at Cantor Global Healthcare Conference](#)
- Sep 13, 2017*  
[Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer](#)
- Sep 6, 2017*  
[Amarin to Present at Rodman & Renshaw's Global Investment Conference](#)
- Aug 14, 2017*  
[Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee](#)

**Financials** [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 1, 2017*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)